Upgrades Archives - Page 163 of 188

1 minute read

‘Highly Compelling’ Eye Drug Data Has Wall Street Stampeding To Buy This ‘Large Cap Growth Story.’ Even After $15B In Market Cap Was Added

September 9, 11:14 AM

Morgan Stanley upgraded Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) to Overweight from Equal Weight with a price target of $851, up from $625. The analyst…

REGN

12 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For September 9, 2022

By Benzinga Insights

September 9, 10:40 AM

Upgrades

ADCT

1 minute read

UBS Upgrades 3M to Neutral, Raises Price Target to $126

By Benzinga Newsdesk

September 9, 9:31 AM

UBS analyst Chris Snyder upgrades 3M (NYSE:MMM) from Sell to Neutral and raises the price target from $118 to $126.

MMM

1 minute read

Daiwa Capital Upgrades Coinbase Global to Buy, Maintains $100 Price Target

By Benzinga Newsdesk

September 9, 9:23 AM

Daiwa Capital analyst Carlton Lai upgrades Coinbase Global (NASDAQ:COIN) from Outperform to Buy and maintains $100 price target.

COIN

1 minute read

Morgan Stanley Upgrades Ionis Pharmaceuticals to Overweight, Raises Price Target to $57

By Benzinga Newsdesk

September 9, 7:59 AM

Morgan Stanley analyst Andrew Galler upgrades Ionis Pharmaceuticals (NASDAQ:IONS) from Underweight to Overweight and raises the price target from $30 to $57.

IONS

1 minute read

JP Morgan Upgrades Emera to Neutral, Raises Price Target to C$66

By Benzinga Newsdesk

September 9, 7:41 AM

JP Morgan analyst Richard Sunderland upgrades Emera (TSX:EMA) from Underweight to Neutral and raises the price target from C$63 to C$66.

TSX:EMA

1 minute read

B of A Securities Upgrades Elevance Health to Buy, Raises Price Target to $575

By Benzinga Newsdesk

September 9, 6:47 AM

B of A Securities analyst Kevin Fischbeck upgrades Elevance Health (NYSE:ELV) from Neutral to Buy and raises the price target from $535 to $575.

ELV

1 minute read

Morgan Stanley Upgrades Regeneron Pharmaceuticals to Overweight, Raises Price Target to $851

By Benzinga Newsdesk

September 9, 6:21 AM

Morgan Stanley analyst Matthew Harrison upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) from Equal-Weight to Overweight and raises the price target from $625 to $851.

REGN